Cidara Therapeutics (CDTX) Misses Q2 EPS by 2051c

Cidara Therapeutics (NASDAQ: CDTX) reported Q2 EPS of ($20.65), $20.51 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $6.95 million.

For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Venu Holding enters $250 million at-the-market stock offering agreement
• Ticketplus files for IPO with shares priced between $13-$15